Skip to main content

amoxicillin

Generic: AMOXICILLIN·Brand: AMOXICILLIN, AMOXICILLIN PEDIATRIC, AMOXIL, Amoxi Drop, Amoxi-tabs, Augmentin, Betacilin, Biomox, Clavacillin, Clavamox, DISPERMOX, Kesium, LAROTID, MOXATAG, Moxatag, POLYMOX, TRIMOX, Talicia, Trimox, UTIMOX, Umbrellin, WYMOX

amoxicillin: 8 clinical trials tracked.

amoxicillin evidence translation

What we can confirm

8 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about amoxicillin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 2 study sponsors
Clinical Trials (8)

A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

NCT07485010·Phase 2
Not yet recruiting

Primary endpoint: The primary outcome of the Intervention Program is microbiological clearance of Mycobacterium abscessus (MABS) with good tolerance of the interventions.

InterventionalRandomizedopen300 targetStarted 2027-04Completion 2031-07The University of Queensland

Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

NCT07293910·Phase 2·INSM
Recruiting

Primary endpoint: Detection of H pylori eradication difference among the three groups through stool antigen test 4 weeks after completion of therapy.

InterventionalRandomizedopen66 targetStarted 2026-02Completion 2026-121 site · EgyptTanta University

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial

NCT06131021·Phase 3
Completed

Primary endpoint: Probing Depth (PD) in millimeters

InterventionalRandomizeddouble236 enrolledStarted 2024-04Completion 2026-041 site · United StatesRutgers, The State University of New Jersey

14-day Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in the Treatment of Helicobacter Pylori Infection Complicated With Functional Dyspepsia:A Single-Center,Randomized Controlled Study

NCT06340724·Phase 3·INSM
Completed

Primary endpoint: Helicobacter pylori eradication rate

InterventionalRandomizedopen104 enrolledStarted 2024-02Completion 2025-011 site · ChinaNanjing First Hospital, Nanjing Medical University

PROMIZE: A Phase I/II Trial to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Oral Combination Antibiotic Therapy to Modulate the Microbiome in Combination With Enzalutamide With Metastatic Castration Resistant Prostate Cancer (mCRPC).

NCT06126731·Phase 1·UTHR
Recruiting

Primary endpoint: Confirm the safety and tolerability of the combination of amoxicillin plus metronidazole (2 weeks) followed by ciprofloxacin plus vancomycin (2 weeks) along with enzalutamide in Phase I in mCRPC patients.

Interventionalopen39 targetStarted 2023-11Completion 2027-062 sites · Switzerland, United KingdomInstitute of Cancer Research, United Kingdom

Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial

NCT05977868·Phase 4
Terminated

Primary endpoint: Cure/Control at 3 Months

InterventionalRandomizedsingle94 targetStarted 2023-08Completion 2025-021 site · United StatesWest Virginia University

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting

Primary endpoint: M/P ratio

Observational1,600 targetStarted 2018-10Completion 2027-0722 sites · Canada, United StatesDuke University

Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (Relais Oral Dans le Traitement Des Endocardites à Streptocoques Multi-sensibles)

NCT02701595·Phase 3·INSM
Completed

Primary endpoint: Treatment failure

InterventionalRandomizedopen324 enrolledStarted 2016-02Completion 2023-0645 sites · FranceUniversity Hospital, Tours